Literature DB >> 7275518

Preoperative arterial occlusion in renal tumors: 3 years experience.

G Mobilio, A Cavalli, G Bianchi.   

Abstract

The authors describe their experience in preoperative embolization of 42 renal neoplasms. In all cases but one Gelfoam has been used for arterial occlusion with just a few and transient complications. Good hemostatic effect and décollement have been obtained irrespective of the diameter and vascularization of the tumor. To avoid late décollement difficulties and reduce the duration of clinical sequels the authors prefer, at present, to resort to surgery within 24 hours of embolization.

Entities:  

Mesh:

Year:  1981        PMID: 7275518     DOI: 10.1007/BF02082068

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.370


  5 in total

1.  Elective transcatheter renal artery occlusion prior to nephrectomy.

Authors:  Y Ben-Menachem; C M Crigler; J N Corriere
Journal:  J Urol       Date:  1975-09       Impact factor: 7.450

2.  Percutaneous catheter-aided infarction of renal tumors: a preliminary report.

Authors:  S B Paster; P Bergreen; H Schwarz
Journal:  J Urol       Date:  1975-09       Impact factor: 7.450

3.  Transcatheter embolization of renal cell carcinoma.

Authors:  H M Goldstein; H Medellin; M T Beydoun; S Wallace; Y Ben-Menachem; R B Bracken; D E Johnson
Journal:  Am J Roentgenol Radium Ther Nucl Med       Date:  1975-03

4.  Percutaneous infarction of renal tumors: comparison between gelatin sponge embolization and cyanoacrylate occlusion.

Authors:  A R Goldin; D R Barnes; I Jacobsen
Journal:  Urology       Date:  1978-02       Impact factor: 2.649

5.  Mechanical devices for arterial occlusion.

Authors:  C Gianturco; J H Anderson; S Wallace
Journal:  Am J Roentgenol Radium Ther Nucl Med       Date:  1975-07
  5 in total
  1 in total

Review 1.  Role of embolization in the treatment of renal masses.

Authors:  David Li; Bradley B Pua; David C Madoff
Journal:  Semin Intervent Radiol       Date:  2014-03       Impact factor: 1.513

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.